Precision medicine company Avilar Therapeutics has raised an additional USD 15 million via its seed funding round from new investors Sanofi Ventures, Medical Excellence Capital, and Astellas Venture Management. This brings the total funds raised in the seed funding round to USD 75 million, after its initial seed funding round raised USD 60 million in November 2021 . Further, Paulina Hill, Partner at Sanofi Ventures will join the company’s board of directors.

The new funds will be used towards advancing its pipeline drug candidates targeting ec, and expanding its proprietary technologies. In addition, the funds will be used towards the growth of the company. 

Avilar is focused on the discovery and development of drugs using a precision medicine approach by targeting protein degraders called ATACs (Asialoglycoprotein receptor Targeting Chimeras) to selectively shuttle disease-causing proteins. The company uses its proprietary discovery platform to design and synthesize ATAC in the drug development process. Further, the company’s pipeline of ATAC-targeting drugs is focused on treating autoimmune, neurological, and other diseases.